echosensNA Profile Banner
Echosens North America Profile
Echosens North America

@echosensNA

Followers
431
Following
400
Media
292
Statuses
637

We envision a future where medical professionals and their patients have the best tools and information to simply and effectively assess and manage liver health

Waltham, MA
Joined March 2016
Don't wanna be here? Send us removal request.
@echosensNA
Echosens North America
5 years
To stay up-to-date on the latest trends and news in non-invasive chronic liver disease management, follow us on @Echosens global page. 👍 #liverhealthmatters https://t.co/H4VAXAysiV
1
0
2
@echosensNA
Echosens North America
6 years
Are you aware of the relationship between #NAFLD, an asymptomatic condition characterized by elevated levels of fat in the liver, and #diabetes? Find out why #T2DM patients should be monitored for #NAFLD. https://t.co/p2MqzzqJSt
0
0
2
@echosensNA
Echosens North America
6 years
New recommendations from the USPSTF recommend screening for #HBV infection in adolescents and adults at increased risk for infection. Learn more: https://t.co/uvQl1LTCBY
aafp.org
The U.S. Preventive Services Task Force recently issued a draft recommendation statement and draft evidence review on screening for hepatitis B virus infection in nonpregnant adolescents and adults.
0
0
1
@phil_newsome7
Phil Newsome
6 years
🙌#easl
@EASLnews
EASLnews
6 years
This International Nurses Day #IND2020, EASL Viewpoints https://t.co/HM6xj27mUh interviews UK #liver nurse educator Michelle Clayton on the year of the nurse, the challenges nurses face during #COVID19, their qualities & skills & offers a message for the future. @EASLedu
0
2
2
@echosensNA
Echosens North America
6 years
Join echosens in our next educational webinar as we welcome physician expert Dr. Caroline Apovian, the Director of Nutrition and Weight Management at Boston Medical Center. Click for details! https://t.co/gPnk7mOTlO
0
0
0
@echosensNA
Echosens North America
6 years
The silent liver diseases you need to know about, #NAFLD and #NASH. Affecting the livers of more than 100 million Americans, NAFLD and NASH can lead to cirrhosis of the #liver and liver cancer. Get the facts so you can prevent these diseases: https://t.co/xgu5CzOqhK
1
0
0
@echosensNA
Echosens North America
6 years
Fatty liver disease is a chronic liver disease and a rapidly growing problem. Find out how Dr. Richard Gilroy of Intermountain Healthcare's liver transplantation program is addressing this problem. https://t.co/ZfndYrZXg7 #liverhealthmatters #NAFLD
0
0
1
@echosensNA
Echosens North America
6 years
A recent study unveiled that #FibroScan was highly effective at non-invasively assessing liver fibrosis in #alcoholic patients and that instant screening of liver fibrosis in heavy drinkers is feasible without a liver biopsy. Learn more: https://t.co/RsOYTzs6we
0
0
0
@echosensNA
Echosens North America
6 years
Clinically #alcoholicliverdisease patients can be asymptomatic or present with acute severe alcoholic hepatitis with and without #cirrhosis.
0
0
0
@echosensNA
Echosens North America
6 years
April is #alcoholawarenessmonth! Did you know an estimated 7% of the US population meets the criteria for #alcoholabuse? These individuals are at increased risk of developing #alcoholicliverdisease, the 8th most common cause of mortality in the US. #liverhealthmatters
2
0
0
@echosensNA
Echosens North America
6 years
From all of us at Echosens, a special thank you to all the doctors and healthcare professionals for everything they are doing to fight #COVID19. #healthcareheroes
0
0
3
@echosensNA
Echosens North America
6 years
Worldwide, 292M people are chronically infected with chronic hepatitis B. Find out the impact #NASH has on these individuals in the latest webinar from Dr. Robert Gish, the Medical Director of The Hepatitis B Foundation. Register Today: https://t.co/ecR1E8E6mk
0
2
4
@echosensNA
Echosens North America
6 years
Discover new innovative tools that support diagnosis efficiency, improve accuracy and reduce costs in the battle against #liverdisease. https://t.co/RqfrVTcUJx #liverhealthmatters
0
0
1
@edwardtate
Ed Tate
6 years
Thank you to Dr. Gish & the good folks @EchosensNA for making this webinar happen. @HepBFoundation
@echosensNA
Echosens North America
6 years
Join Echosens as we welcome Dr. Robert Gish, the Medical Director for the Hepatitis B Foundation, as he presents new findings on the intersection of #HBV, #NASH and #T2DM. Learn More: https://t.co/SFvSCWdY33
0
1
1
@echosensNA
Echosens North America
6 years
Join Echosens as we welcome Dr. Robert Gish, the Medical Director for the Hepatitis B Foundation, as he presents new findings on the intersection of #HBV, #NASH and #T2DM. Learn More: https://t.co/SFvSCWdY33
0
0
3
@echosensNA
Echosens North America
6 years
Echosens proudly announces its collaboration with MetaPhy Health to support turn-key, comprehensive #chronicliverdisease management services to #gastroenterology practices for their patients with #fattyliverdisease. Learn More: https://t.co/1G9muuWlY8
0
0
4
@echosensNA
Echosens North America
6 years
Today is #diabetesalertday! Did you know that the prevalence of #NAFLD has increased in parallel with the epidemics of #T2DM and #obesity? Help us raise awareness of the relationship between #NAFLD and #diabetes. Learn more: https://t.co/AfIHtXpUbe #liverhealthmatters
0
1
2
@echosensNA
Echosens North America
6 years
Today is #diabetesalertday! Did you know that the prevalence of #NAFLD has increased in parallel with the epidemics of #T2DM and #obesity? Help us raise awareness of the relationship between #NAFLD and #diabetes. Learn more: https://t.co/CHg9lk9OAG #liverhealthmatters
0
2
0
@echosensNA
Echosens North America
6 years
Echosens has arranged an independent assessment conducted by Santa Barbara Actuaries, a healthcare consulting firm specializing in predictive modeling and analytics, to determine the cost savings of #FibroScan care models at the #pointofcare. Learn More: https://t.co/rZxevUvzz2
0
1
1
@phil_newsome7
Phil Newsome
6 years
@CovidHep
COVID-HEP
6 years
Happy to announce that @CovidHep is now endorsed by @EASLedu Alongside our American partners @SecureCirrhosis and @AASLDtweets we can hopefully begin to understand the impact of COVID-19 in patients with liver disease. Join the effort, visit at
0
3
10